Literature DB >> 8223832

Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study.

T H Grasela1, J B Fiedler-Kelly, C Salvadori, C Marey, R Jochemsen, H Loo.   

Abstract

The predictive ability of population pharmacokinetic parameters of tianeptine, obtained from a mixed effect analysis of pre-marketing pharmacokinetic studies, was evaluated using tianeptine plasma concentrations obtained during a large multi-center post-marketing surveillance study. The mean prediction error was 7.8 ng.ml-1 and the root mean square prediction error was 52.1 ng/ml when initial estimates of population pharmacokinetic parameters were used to predict drug concentrations in one half of the post-marketing data. When the population parameters were revised to reflect the data collected in the first half of the post-marketing study, the mean prediction error was reduced to -3.2 ng.ml-1 and the root mean square prediction error was reduced to 29.5 ng.ml-1. These results suggest that population pharmacokinetic parameters obtained from pre-marketing data may not accurately predict drug concentrations in patients receiving the drug in the post-marketing setting. Once the population parameters are updated to reflect data from the post-marketing period, the predictive ability of the data-base increases, but substantial variability in the prediction error remains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223832     DOI: 10.1007/bf00315492

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Ion-pair extraction and high-performance liquid chromatographic determination of tianeptine and its metabolites in human plasma, urine and tissues.

Authors:  G Nicot; G Lachatre; C Gonnet; J Mallon; E Mocaer
Journal:  J Chromatogr       Date:  1986-08-22

2.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

3.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

4.  Long-term use of tianeptine in 380 depressed patients.

Authors:  H Lôo; H Ganry; H Dufour; J D Guelfi; R Malka; J P Olié; H Scharbach; J Tignol; C Marey; A Kamoun
Journal:  Br J Psychiatry Suppl       Date:  1992-02

5.  Development of a population pharmacokinetic database for tianeptine.

Authors:  T H Grasela; J B Fiedler-Kelly; C Salvadori; C Marey; R Jochemsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

  6 in total
  2 in total

1.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 2.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.